Nasdaq · Common Stock · Pharmaceutical Preparations
American publicly traded generics and specialty pharmaceutical company
32 entities across 11 jurisdictions. Read directly from the company’s own 10-K EX-21 filed 2026-02-27 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Amedra Pharmaceuticals LLC | Delaware | |
| Amneal Healthcare Private Ltd. | India | |
| Amneal Complex Products, Research LLC | Delaware | |
| Amneal EU, Limited | Ireland | |
| Amneal Ireland Limited | Ireland | |
| Amneal Ireland Holdings Limited | Ireland | |
| Amneal Oncology Private Limited | India | |
| Amneal Pharma Germany GmbH | Germany | |
| Amneal Pharmaceuticals Private Limited | India | |
| Amneal Pharmaceuticals Dutch Holding Company, LLC | Delaware | |
| Amneal Pharmaceuticals Holding Gmbh | Switzerland | |
| Amneal Pharmaceuticals LLC | Delaware | |
| Amneal Pharmaceuticals of New York, LLC | Delaware | |
| Amneal Singapore Private Ltd. | Singapore | |
| Amneal UK Holding Company Limited | United Kingdom | |
| Amneal Biosciences LLC | Delaware | |
| Amneal Intermediate Inc. | Delaware | |
| Amneal Biopharma Solutions Private Limited | India | |
| Amneal Biopharma Synthesis Private Limited | India | |
| AvKARE, LLC | Tennessee | |
| Dixon-Shane LLC | Kentucky | |
| Gemini Laboratories, LLC | Delaware | |
| Impax Laboratories USA, LLC | California | |
| Impax Laboratories, LLC | Delaware | |
| Mountain, LLC | Delaware | |
| Puniska Healthcare Mexico SA De CV | Mexico | |
| RAKS Pharma Private Limited | India | |
| Rondo Acquisition LLC | Delaware | |
| Rondo Holdings, LLC | Delaware | |
| Rondo Intermediate Holdings, LLC | Delaware | |
| Rondo Partners, LLC | Delaware | |
| Trail Services, LLC | Delaware |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $2.0B | $91.1M | $322.6M | 31.5% | 148,913,000 |
| FY2021 | $2.1B | $13.2M | $194.1M | 36.7% | 151,821,000 |
| FY2022 | $2.2B | −$270.6M | $18.7M | 35.5% | 150,944,000 |
| FY2023 | $2.4B | −$79.3M | $302.4M | 34.3% | 176,136,000 |
| FY2024 | $2.8B | −$116.9M | $243.2M | 36.5% | 308,978,000 |
| FY2025 | $3.0B | $72.1M | $269.9M | 36.9% | 324,805,000 |
13 institutions tracked — 7 added, 5 reduced, 1 opened a new position, 1 sold out. Index money added 3,198,577 shares while active managers cut 251,563.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| BlackRock, Inc. | Index | 26,562,093 | +2,042,901 | $459.8M |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 5,139,449 | +593,401 | $89.0M |
| STATE STREET CORP | Index | 7,356,977 | +562,275 | $127.3M |
| CITADEL ADVISORS LLC | Hedge fund | 1,148,015 | +528,596 | $19.9M |
| MORGAN STANLEY | Active fund | 4,110,028 | −527,157 | $71.1M |
| RENAISSANCE TECHNOLOGIES LLC | Hedge fund | 87,487 | −189,150 | $1.5M |
| JPMORGAN CHASE & CO | Active fund | 795,000 | −187,303 | $13.9M |
| BANK OF AMERICA CORP /DE/ | Active fund | 795,537 | +118,742 | $13.8M |
| AQR CAPITAL MANAGEMENT LLC | Hedge fund | 795,028 | −69,764 | $13.8M |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 230,997 | +48,056 | $4.0M |
| FMR LLC | Active fund | 825,120 | +33,110 | $14.3M |
| WELLINGTON MANAGEMENT GROUP LLP | Active fund | 55,772 | −6,693 | $965,414 |
NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
Amneal Pharmaceuticals, Inc. files under SIC 2834 — all 50 pharmaceutical preparations companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
